Article
Synthesis and preclinical evaluation of two osimertinib isotopologues labeled with carbon-11 as PET tracers targeting the tyrosine kinase domain of the epidermal growth factor receptor.
Nuclear medicine and biology - 1 Jan 2000
Högnäsbacka Antonia, Poot Alex J, Kooijman Esther, Schuit Robert C, Schreurs Maxime, Verlaan Mariska, van den Hoek Johan, Heideman Daniëlle A M, Beaino Wissam, van Dongen Guus A M S, Vugts Danielle J, Windhorst Albert D
Abstract excerpt
INTRODUCTION: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) that is able to inhibit the EGFR treatment resistance mutation T790M and primary EGFR mutations Del19 and L858R. The aim of the study was to evaluate the potential of carbon-11 labeled osimertinib to be used as a tracer for the PET imaging of tumors bearing the T790M mutation. METHODS: Osimertinib was labeled with carbon-11 at two...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.